Associated Genetic Biomarkers
Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (PTGS2) is a gene that encodes a protein that is the key enzyme in prostaglandin biosynthesis. Missense mutations, silent mutations, and nonsense mutations are observed in cancers such as skin cancer, colon cancer, and endometrial cancer.
PTGS2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains PTGS2 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with PTGS2 status in the inclusion eligibility criteria most commonly target breast carcinoma .
Significance of PTGS2 in Diseases
Breast Carcinoma +
PTGS2 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTGS2 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.